calcimimetic

Any drug that acts like calcium, for example, that lowers serum parathyroid hormone levels.

calcimimetic

Of any drug that increases activation of CALCIUM-SENSING RECEPTORS. Calcimimetics show promise in the treatment of hyperparathyroid states. Compare CALCILYTIC.

Mentioned in ?

References in periodicals archive ?

If approved, etelcalcetide will be the first calcimimetic agent that can be administered intravenously.

FDA Accepts Amgen's New Drug Application For Novel Intravenous Calcimimetic Etelcalcetide

Parathyroidectomy may now be necessary or expensive calcimimetic drugs must be administered to try to restore the disordered metabolic environment.

Important complications of chronic kidney disease

In many patients with moderate to severe sHPT, cinacalcet, an oral-only calcimimetic agent, is also required, and for some, surgical therapy (typically subtotal parathyroidectomy [PTX]) may be necessary (National Kidney Foundation 2003).

Reforming Medicare's dialysis payment policies: implications for patients with secondary hyperparathyroidism

Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and healthrelated quality of life in secondary hyperparathyroidism.

The patients with primary hyperparathyroidism: evaluation of the last two years / Primer Hiperparatiroidili Hastalarimiz: Son iki Yilin Degerlendirmesi

Elevated iPTH levels caused by secondary hyperparathyroidism in chronic kidney disease patients are generally treated with either a vitamin D receptor activator like Zemplar or a calcimimetic like cinacalcet, or additionally, may be treated with the combination of a vitamin D receptor activator plus a calcimimetic.

New Publication Presents Comparative Efficacy Data for Abbott's Zemplar[R] (paricalcitol) in Treating Secondary Hyperparathyroidism in Hemodialysis Patients

Cinacalcet is a calcimimetic drug, which lowers PTH without increasing calcium or phosphorus.

Update on the new Kidney Disease: Improving Global Outcomes (KDIGO) guidelines for mineral and bone disorders (MBD)--a focus on medications

This finding diametrically changes the treatment strategy to controlling the effects of CKD on the cardiovascular system by decreasing the serum phosphorus and on the PTH concentration by using a calcimimetic agent, because the presence of hypercalcemia contraindicates increasing the dose of vitamin D analogs.

A case of renal osteodystrophy with unexpected serum intact parathyroid hormone concentrations

Calcimimetic agents: Calcium is not a unique ligand for the CaR, although it is the only one with a convincing physiological role.

Role of calcium-sensing receptor in bone biology

Cinacalcet is a type II calcimimetic agent with a novel mechanism of action (7, 11).

Cinacalcet hydrochloride (Sensipar)

The company also announced that its first-in-class oral calcimimetic, Mimpara, known as Sensipar in the US, has received regulatory approval in the European Union (EU).

Amgen trial will evaluate impact of treating anemia on cardiovascular risks in patients with CKD, type 2 diabetes

Mittman and his colleagues found that as cinacalcet bonded to the calcium receptors, calcimimetic compound was able to regulate parathyroid hormone (PTH) secretion, he reported in a poster at a meeting on clinical nephrology sponsored by the National Kidney Foundation.

Cinacalcet lowers PTH and calcium in dialysis patients

Sensipar is an innovative, first-in-class oral calcimimetic indicated for the treatment of secondary HPT in CKD patients on dialysis, and for the treatment of elevated calcium levels (hypercalcemia) in patients with parathyroid carcinoma.

Amgen Launches Landmark Trial to Evaluate the Impact of Treating Anemia on Cardiovascular Risks in Patients with Chronic Kidney Disease and Type 2 Diabetes

CITE

Site: Follow: Share:

Open / Close